# Role of Intralipid in Management of Organophosphorus Poisoning

> **NCT04393103** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Amani Hassan Abdel-Wahab**

## Conditions studied

- Organophosphorus Poisoning

## Interventions

- **DRUG:** Intralipid, 20% Intravenous Emulsion
- **DRUG:** Intravenous Atropine Sulfate

## Key facts

- **NCT ID:** NCT04393103
- **Lead sponsor:** Amani Hassan Abdel-Wahab
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no avilable resorces
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04393103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04393103, "Role of Intralipid in Management of Organophosphorus Poisoning". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04393103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*